Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Medivir AB ( (SE:MVIR) ) has issued an update.
Medivir AB reported its interim financial results for January to September 2025, showing a decrease in losses and cash flow from operations. The company received a patent approval in Japan for its fostrox and lenvatinib combination, enhancing its intellectual property protection. Medivir plans a new share issue to fund a pivotal study of fostrox in combination with Lenvima for second-line liver cancer treatment. Additionally, Medivir signed an exclusive license agreement with Biossil, Inc. for the development of remetinostat, potentially yielding significant milestone payments and royalties.
The most recent analyst rating on (SE:MVIR) stock is a Buy with a SEK54.00 price target. To see the full list of analyst forecasts on Medivir AB stock, see the SE:MVIR Stock Forecast page.
More about Medivir AB
Medivir AB is a pharmaceutical company focused on developing innovative cancer drugs, particularly targeting areas with high unmet medical needs. The company is dedicated to advancing fostroxacitabine bralpamide (fostrox), aimed at treating liver cancer with minimal side effects. Medivir’s business model emphasizes collaborations and partnerships, and its shares are listed on Nasdaq Stockholm’s Small Cap list.
Average Trading Volume: 525,437
Technical Sentiment Signal: Sell
Current Market Cap: SEK57.65M
For detailed information about MVIR stock, go to TipRanks’ Stock Analysis page.